Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Quan Sing Ng's publication output changed over time?
ScholarIQpublication output · 2006–2023
Output grew0% over the shown period — from 1 works in 2006 to 1 in 2023.
1
1
2
1
3
1
1
1
20062012201620172019202120222023
What are the most-cited papers on Quan Sing Ng?
ScholarIQmost cited works
Non–Small Cell Lung Cancer: Histopathologic Correlates for Texture Parameters at CT
Balaji Ganeshan, Vicky Goh, Henry Mandeville, Quan Sing Ng, Peter Hoskin, Kenneth A. Miles
S50280174. 2012454 Citations
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
Matthew R. Smith, Chris Parker, Fred Saad, Kurt Miller, Bertrand Tombal, Quan Sing Ng, Martin Boegemann, Vsevolod Matveev, Josep M. Piulats, Luis Eduardo Rosa Zucca, Oleg Karyakin, Go Kimura, Nobuaki Matsubara, William Carlos Nahas, Franco Nolè, Eli Rosenbaum, Axel Heidenreich, Yoshiyuki Kakehi, Amily Zhang, Heiko Krissel, Michael Teufel, Junwu Shen, Volker Jean Wagner, Celestia S. Higano
The Lancet Oncology. 2019407 CitationsOPEN ACCESS
Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis
Aaron C. Tan, Gillianne Lai, Gek San Tan, Shou Yu Poon, Brett Doble, Tse Hui Lim, Zaw Win Aung, Angela Takano, Wan Ling Tan, Mei‐Kim Ang, Bien Soo Tan, Devanand Anantham, Chow Wei Too, Apoorva Gogna, Boon‐Hean Ong, Tina Koh, Ravindran Kanesvaran, Quan Sing Ng, Amit Jain, Tanujaa Rajasekaran, Alvin S.T. Lim, Wan Teck Lim, Chee‐Keong Toh, Eng-Huat Tan, Tony Kiat Hon Lim, Daniel S.W. Tan
Lung Cancer. 2019124 Citations
Clonal <i>MET</i> Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer
Gillianne Lai, Tse Hui Lim, John Lim, Perry J.R. Liew, Xue Lin Kwang, Rahul Nahar, Zaw Win Aung, Angela Takano, Yin Yeng Lee, Dawn Pingxi Lau, Gek San Tan, Sze Huey Tan, Wan Ling Tan, Mei‐Kim Ang, Chee‐Keong Toh, Bien Soo Tan, Devanand Anantham, Chow Wei Too, Apoorva Gogna, Boon Hean Ong, Tina Koh, Ravindran Kanesvaran, Quan Sing Ng, Amit Jain, Tanujaa Rajasekaran, Ju Yuan, Tony Kiat Hon Lim, Alvin S.T. Lim, Axel M. Hillmer, Wan Teck Lim, N. Gopalakrishna Iyer, Wai Leong Tam, Weiwei Zhai, Eng-Huat Tan, Daniel Shao-Weng Tan
Journal of Clinical Oncology. 2019119 Citations
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial
Anthony T.�C. Chan, V.H.F. Lee, R-L. Hong, M-J. Ahn, Wan Qin Chong, S. B. Kim, Gwo Fuang Ho, Priscilla B. Caguioa, Nuttapong Ngamphaiboon, Cheryl Ho, Mubashir Aziz, Quan Sing Ng, C-J. Yen, Nopadol Soparattanapaisarn, Roger KC Ngan, S.K. Kho, M.L.A. Tiambeng, Tak Yun, Virote Sriuranpong, Alain P. Algazi, Andy S. K. Cheng, Erminia Massarelli, Ramona F. Swaby, Sanatan Saraf, Jianda Yuan, Lillian L. Siu
Annals of Oncology. 2022113 CitationsOPEN ACCESS
Related on ScholarIQ
National Cancer Centre Singapore
Institution
Non–Small Cell Lung Cancer: Histopathologic Correlates for Texture Parameters at CT
Paper
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
Paper
Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis
Paper
Clonal <i>MET</i> Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer
Paper
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial
Paper